SUBSCRIBE
SUBSCRIBE
Biotech Bay

Geron Corporation: Recent Advances in Cellular Reprogramming

November 21, 2007 | 
1 min read

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today commented on the impact of recent advances in cellular reprogramming on the development of human embryonic stem cell (hESC)-based therapies.

MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: 3D image of a KRAS oncogene
Business
BridgeBio Spins Out Oncology Company with $200M in Financing
May 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bristol Myers Squibb office in California
Biotech Bay
BMS Taps Cellares in $380M CAR T Cell Therapy Manufacturing Agreement
April 22, 2024
 · 
2 min read
 · 
Tyler Patchen